Literature DB >> 20349072

Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis.

V F Azevedo1, R Pecoits-Filho.   

Abstract

Ankylosing spondylitis (AS) is a systemic inflammatory rheumatic disease characterized primarily by axial joint involvement, sacroiliitis and various extra-articular manifestations. High cardiovascular mortality in AS has led many researchers to investigate possible risk factors involved with cardiovascular disease in these patients. This review summarizes published data concerning endothelial dysfunction and atherosclerosis in patients with AS. The author discusses current limitations and problems related to a better assessment of these two possible changes in AS.

Entities:  

Mesh：

Year:  2010        PMID： 20349072     DOI： 10.1007/s00296-010-1416-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  61 in total

Review 1.  The clinical implications of endothelial dysfunction.

Authors:  Michael E Widlansky; Noyan Gokce; John F Keaney; Joseph A Vita
Journal:  J Am Coll Cardiol       Date:  2003-10-01       Impact factor: 24.094

Review 2.  Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.

Authors:  Ira Tabas; Kevin Jon Williams; Jan Borén
Journal:  Circulation       Date:  2007-10-16       Impact factor: 29.690

3.  [Vascular wall lesion and disorder of endothelial vasoregulating function in patients with ankylosing spondylitis].

Authors:  N A Karoli; A P Rebrov
Journal:  Klin Med (Mosk)       Date:  2007

4.  Impaired endothelial function in patients with ankylosing spondylitis.

Authors:  I Sari; T Okan; S Akar; H Cece; C Altay; M Secil; M Birlik; F Onen; N Akkoc
Journal:  Rheumatology (Oxford)       Date:  2005-10-04       Impact factor: 7.580

Review 5.  Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities.

Authors:  Robert S Rosenson
Journal:  Curr Opin Cardiol       Date:  2005-07       Impact factor: 2.161

Review 6.  Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.

Authors:  J Braun; J Sieper; M Breban; E Collantes-Estevez; J Davis; R Inman; H Marzo-Ortega; H Mielants
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

7.  Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension.

Authors:  Maurizio Galderisi; Silvana Cicala; Pio Caso; Luigi De Simone; Arcangelo D'Errico; Antonio Petrocelli; Oreste de Divitiis
Journal:  Am J Cardiol       Date:  2002-10-15       Impact factor: 2.778

Review 8.  Vascular endothelial growth factor: a key mediator of neoangiogenesis. A review.

Authors:  A Amoroso; F Del Porto; C Di Monaco; P Manfredini; A Afeltra
Journal:  Eur Rev Med Pharmacol Sci       Date:  1997 Jan-Jun       Impact factor: 3.507

9.  Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

10.  Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor.

Authors:  I-L Engvall; A-C Elkan; B Tengstrand; T Cederholm; K Brismar; I Hafstrom
Journal:  Scand J Rheumatol       Date:  2008 Sep-Oct       Impact factor: 3.641
View more
  10 in total

1.  IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents.

Authors:  Valderilio Feijó Azevedo; J R Faria-Neto; Andrea Stinghen; Pedro G Lorencetti; Wagner P Miller; Beatriz P Gonçalves; Carla C Szyhta; Roberto Pecoits-Filho
Journal:  Rheumatol Int       Date:  2013-01-08       Impact factor: 2.631

2.  Endothelial Progenitor Cells as a Marker of Endothelial Dysfunction and Atherosclerosis in Ankylosing Spondylitis: A Cross-Sectional Study.

Authors:  Inderjeet Verma; Ashit Syngle; Pawan Krishan; Nidhi Garg
Journal:  Int J Angiol       Date:  2016-10-03

3.  Thrombin generation in ankylosing spondylitis.

Authors:  Clément Prati; Evelyne Racadot; Jean-Pierre Cedoz; Daniel Wendling
Journal:  Clin Rheumatol       Date:  2010-08-17       Impact factor: 2.980

Review 4.  Cardiovascular Morbidity in Ankylosing Spondylitis: A Focus on Inflammatory Cardiac Disease.

Authors:  Pradnya Brijmohan Bhattad; Mugdha Kulkarni; Parasbhai D Patel; Mazen Roumia
Journal:  Cureus       Date:  2022-06-03

Review 5.  The Sphinx's riddle: cardiovascular involvement in autoimmune rheumatic disease.

Authors:  Sophie Mavrogeni; George Markousis-Mavrogenis; Genovefa Kolovou
Journal:  BMC Cardiovasc Disord       Date:  2016-10-28       Impact factor: 2.298

6.  Adalimumab and sulfasalazine in alleviating sacroiliac and aortic inflammation detected in PET/CT in patients with axial spondyloarthritis: PETSPA.

Authors:  Juha-Pekka Kaijasilta; Anne M Kerola; Riitta Tuompo; Heikki Relas; Antti Loimaala; Hannu Koivu; Jukka Schildt; Tuomas Kerola; Kari Eklund; Markku J Kauppi; Tuomo V M Nieminen
Journal:  Immun Inflamm Dis       Date:  2021-11-09

Review 7.  Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.

Authors:  Theodoros Dimitroulas; Aamer Sandoo; George D Kitas
Journal:  Int J Mol Sci       Date:  2012-09-26       Impact factor: 5.923

8.  Is there a relationship between endothelial nitric oxide synthase gene polymorphisms and ankylosing spondylitis?

Authors:  Ismail Sari; Yusuf Ziya Igci; Gercek Can; Ali Taylan; Dilek Solmaz; Bulent Gogebakan; Servet Akar; Zeynep Eslik; Giray Bozkaya; Nurullah Akkoc
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

9.  Spondyloarthritis Patients Suffer Increased Risk of Renal Complications Compared With General Population: A Retrospective Observational Study.

Authors:  Min Xiao; Qing Lv; Yanli Zhang; Liudan Tu; Mingcan Yang; Zhiming Lin; Zetao Liao; Yutong Jiang; Xuqi Zheng; Xiaomin Li; Qiujing Wei; Shuangyan Cao; Jieruo Gu
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

10.  Effects of Therapies on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.

Authors:  Paras Karmacharya; Ravi Shahukhal; Cynthia S Crowson; M Hassan Murad; John M Davis; Pragya Shrestha; Delamo Bekele; Kerry Wright; Rikesh Chakradhar; Maureen Dubreuil
Journal:  Rheumatol Ther       Date:  2020-11-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.